Experimental studies of oxymatrine
and its mechanisms of action
in hepatitis B and C viral infections.
by Wu XN & Wang GJ
Department of Hepato-Gastroenterology,
Shanghai First People's Hospital, Shanghai, China.
OBJECTIVE
Viral hepatitis B is a worldwide
public health problem; in China, chronic hepatitis B patients
account for 30-40 million people and chronic hepatitis C accounts
for 16% of all chronic hepatitis patients. Interferon-alpha
(IFNalpha) is rather expensive and has many serious side-effects,
which makes practitioners prudent in its use. METHOD/RESULTS:
A multicenter study held in China showed that the negative
seroconversion of HBV DNA by oxymatrine and IFNalpha-1b was
42.3% and 40.7%, respectively, and that of HBeAg was 36.5%
and 38.9%, respectively, after 3 months treatment with each
in patients with chronic hepatitis. CONCLUSIONS: Oxymatrine
has a similar efficacy to IFNalpha, but with no adverse effects
apart from slight injection pain, and it is much less expensive.
For more information on Oxymatrine,
please click below.
Oxymatrine
Article 2, Oxymatrine Article 3